This site is intended for U.S. healthcare professionals.
Menu
Close
ISGA SUCCESS
ISGA Clear or Almost Clear
Tab Number 3
At Baseline, 38.0% of the patients had an ISGA score of 2 (Mild), and 61.3% had an ISGA score of 3 (Moderate)2
Please see Phase 3 Pivotal Trial Results in patients 2 years and older under Efficacy and Safety.
*Eligible patients pay as little as $10
Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1
The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined.
PDE4=phosphodiesterase 4.
EUCRISA (crisaborole) is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.